170 completed, 41 unknown, 40 active not recruiting, 38 recruiting. 157 Phase 2, 93 Phase 3, 43 Phase 1, 21 Not applicable, 18 Phase 4.
Follow this drug Literature Review of Anastrozole trials Research Report on Anastrozole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy - Metastatic Invasive Breast Cancer, Resistant Breast Cancer | Phase 2 | Not yet recruiting | University of California, San Diego | 150 | 2027-07-01 | 2026-07-27 |
| Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males Fulvestrant, Anastrozole (ARIMIDEX™) - Inguinal Hernia Unilateral, Inguinal Hernia Bilateral | Phase 1 | Recruiting | Northwestern University | 30 | 2026-10-02 | 2026-10-06 |
| QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy Iparomlimab and Tuvonralimab (QL1706), Aromatase Inhibitor (AI), CDK4/6 inhibitor - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 40 | 2026-10-01 | 2026-08-26 |
| Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer Fulvestaciclib, Trastuzumab, Pertuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 240 | 2026-10-01 | 2026-07-21 |
| BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder Aromatase Inhibitors, Bupropion, GnRH agonist - Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Illinois at Chicago | 100 | 2026-09-01 | 2026-08-24 |
| Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial Anastrozole, Biospecimen Collection, Bone Scan - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1978 | 2026-08-10 | 2026-10-20 |
| The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans GnRH antagonist, Estradiol (E2), Testosterone - Cerebral Blood Flow, Cerebral Blood Flow Regulation | Not applicable | Not yet recruiting | University of British Columbia | 50 | 2026-04-01 | 2026-02-10 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate - Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes | Not applicable | Enrolling by invitation | Enhanced Emirates Limited | 60 | 2026-03-12 | 2026-05-06 |
| A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer HRS-8080 Tablets, Letrozole tablets, Tamoxifen Citrate Tablets - Breast Cancer | Phase 3 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 5500 | 2026-03-04 | 2026-05-22 |
| Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice Ribociclib, Letrozole, Anastrozole - Breast Cancer | Recruiting | Novartis Pharmaceuticals | 240 | 2026-01-23 | 2026-05-05 | |
| Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study Dalpiciclib 125mg, Dalpiciclib 100mg, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen - Breast Diseases, Breast Neoplasms | Phase 2 | Recruiting | Fujian Cancer Hospital | 2000 | 2026-01-21 | 2026-05-12 |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) LY4064809, Placebo, Ribociclib - Breast Neoplasms, Neoplasm Metastasis | Phase 3 | Recruiting | Eli Lilly and Company | 800 | 2025-12-22 | 2026-10-08 |
| Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia Ribociclib, Letrozole, Anastrozole - Breast Cancer | Recruiting | Novartis Pharmaceuticals | 2766 | 2025-12-03 | 2026-08-10 | |
| Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases Initiation of abemaciclib plus letrozole/anastrozole, Initiation of letrozole/anastrozole - Advanced Breast Cancer | Completed | Brigham and Women's Hospital | 3883 | 2025-11-03 | 2026-05-12 | |
| A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors Sacituzumab Govitecan + Fulvestrant, Sacituzumab Govitecan + Anastrozole / Exemestane - Stage IV (Metastatic) Breast Cancer | Phase 1 | Not yet recruiting | Hunan Cancer Hospital | 12 | 2025-10-01 | 2025-09-16 |
| Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study Trastuzumab rezetecan, Pyrotinib, Dalpiciclib - HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 288 | 2025-09-10 | 2025-09-18 |
| Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients Dalpiciclib, Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) - Early Breast Cancer, Adjuvant Therapy | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 200 | 2025-09-01 | 2025-08-03 |
| A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer HRS-8080 Tablet, Fulvestrant injection, Exemestane tablets - Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 240 | 2025-07-23 | 2026-10-02 |
| Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg - HER2 Negative Breast Cancer | Phase 2 | Recruiting | Yale University | 140 | 2025-07-09 | 2026-05-26 |
| Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd, Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid, Palbociclib 200mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid - Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 474 | 2025-07-01 | 2025-07-11 |
Showing 20 of 351. Sign in to see all of them.
Breast Neoplasms (246) · Neoplasms (17) · Neoplasm Metastasis (15) · Carcinoma, Intraductal, Noninfiltrating (12) · Breast Diseases (8) · Breast Carcinoma In Situ (7) · Breast Neoplasms, Male (7) · Hypogonadism (7) · Obesity (7) · Arthralgia (5) · Endometrial Neoplasms (5) · Ovarian Neoplasms (5) · Triple Negative Breast Neoplasms (5) · Endometriosis (4) · Insulin Resistance (4)
AstraZeneca (46) · Eli Lilly and Company (10) · Novartis Pharmaceuticals (9) · Fudan University (8) · National Cancer Institute (NCI) (8) · Mayo Clinic (7) · Massachusetts General Hospital (6) · University of Washington (5) · Institute of Cancer Research, United Kingdom (4) · Pfizer (4) · SWOG Cancer Research Network (4) · UNICANCER (4) · Washington University School of Medicine (4) · Alliance for Clinical Trials in Oncology (3) · Dana-Farber Cancer Institute (3)
United States (176) · France (56) · China (51) · Canada (43) · Italy (40) · Spain (40) · Germany (39) · United Kingdom (36) · Belgium (30) · Australia (27) · Japan (27) · South Korea (26) · Brazil (23) · Austria (21) · Netherlands (21)
Frances J Hayes, MD (3) · Hannah Linden (3) · Andrew L. Pecora, MD, FACP (2) · Angel Arnaout, Dr. (2) · Anthony Howell (2)
PMID 15894097, PMID 23902874, PMID 28045625, PMID 32001832, PMID 33149768, PMID 36791166, PMID 38470447, PMID 38979716, PMID 40017004, PMID 42334791, PMID 10076721, PMID 10334533, PMID 10873072, PMID 11502778, PMID 11836290, PMID 11850213, PMID 12207179, PMID 12490681, PMID 12538507, PMID 12804433, PMID 12954578, PMID 15501952, PMID 15597216, PMID 15701892, PMID 15767642, PMID 15980158, PMID 16467120, PMID 16598749, PMID 17110627, PMID 17538978, PMID 17912634, PMID 18258986, PMID 18809056, PMID 18812550, PMID 19470631, PMID 19701242, PMID 19707253, PMID 20012355, PMID 20194852, PMID 20200299, PMID 20586616, PMID 20679610, PMID 20700118, PMID 20938664, PMID 21555689, PMID 21717449, PMID 21792626, PMID 21797916, PMID 21880792, PMID 21885816
2014 (5), 2023 (5), U10CA032102 (4), 2018 (3), P30CA015083 (3), 2005 (2), 2016 (2), 2017 (2), N01CM00099 (2), P30CA006973 (2), P30CA015704 (2), U10CA021115 (2), U10CA180820 (2), 2004 (1), 2008 (1)